Home > Resources > Whitepapers > Patient Identity Management: A Dose of Patient-friendly Security for Medical Providers

Patient Identity Management: A Dose of Patient-friendly Security for Medical Providers

February 16, 2018

Every day, in hospitals and physician offices everywhere, healthcare providers are telling patients what’s good for them: exercise, eat better, quit smoking. No one would deny this is great advice but be getting the patient to follow it can be a challenge for reasons most of us know too well. Ironically, some of these same providers find themselves playing the role of the resistant patient in the evolution of digital healthcare.

Spotlight

Harlem Biospace

Harlem Biospace (Hb) is a new biotech incubator, the first of its kind in New York City, to offer affordable shared wet-lab space for early-stage biotech companies. It offers a beautiful wet lab outfitted with modern biotech equipment, exciting classes and events, and business support – creating a community to turn ideas into inventions that solve real health problems. Harlem Biospace is situated at the heart of three academic campuses (Columbia University, City College of New York, and Columbia’s Manhattanville campus), with easy access to other major universities, the life science community, and the vibrancy of New York City.

OTHER WHITEPAPERS

The biopharmaceutical industry is leading the way in developing vaccines and treatments for COVID-19

whitePaper | April 8, 2020

The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza.

Liposomal and Nanoparticle Technology at Pfizer Melbourne

whitePaper | November 22, 2022

Specializing in oncology, anti-infective and complex formulations, Pfizer Melbourne provides end-to-end services from development through to commercial manufacture of sterile dosage forms.

Biotech Talent Management

whitePaper | February 2, 2022

While many sectors were dealt a severe blow by the COVID-19pandemic, biotech and medtech saw continued growth andare thus attracting top candidates even for non-scientific roles.

Synthetic Biology Biotechnology and AgTech

whitePaper | March 12, 2022

CRISPR, gene editing, biotech, precision agriculture and automation influencing the future of business, government, food, medicine, geopolitics and society

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19